The test report of UWCCG is based on the samples sent by the examinees, using the DNA of intestinal exfoliated cells in feces as the detection target, and fluorescence quantitative PCR technology to detect three genes closely related to the development of bowel cancer, and based on the data of UWCCG's great population-based cohort study, to comprehensively assess the risk of bowel cancer and pre-cancerous lesions of the examinees. If the test results indicate a high risk, it means that the methylation level of the bowel cancer-related genes is abnormal in the test sample, and the risk of colorectal cancer or precancerous lesions is high, so it is recommended to go to the hospital for colonoscopy to confirm whether there are any lesions in the intestinal tract; on the contrary, it means that the methylation level of the bowel cancer-related genes is abnormal in the sample sent to us for testing. As for the accuracy of the test results, data from the 2019-2020 Hua Chang Kang retrospective multi-center clinical validation study showed that Hua Chang Kang has a sensitivity of 88% and specificity of 92% for bowel cancer, and the maturity of the fecal DNA testing technology has also allowed for a wider coverage of the population in the prevention and control of bowel cancer screening.